ABSTRACT Some patients with soft tissue sarcoma (STS) report a history of injury at the site of their tumor.
INTRODUCTION
Soft tissue sarcomas (STS) represent a heterogeneous mix of >50 mesenchymal tumor types that together encompass approximately 1% of tumors in adults and 9% of tumors in children (1) (2) (3) . To study sarcoma development, we utilized Pax7
CreER/+ ; Kras LSL-G12D/+ ; Trp53 flox/flox (P7KP) mice because mutations in the Ras and p53 pathways have been reported in human soft tissue sarcoma (4, 5) . Following systemic administration of tamoxifen by intraperitoneal (IP) injection, P7KP mice develop sarcomas throughout the animal in 6-8 weeks (6) . The most common locations for sarcoma development are the body wall, extremities, and head and neck (6) . Similar to other reports, the histology of the sarcomas in P7KP mice exist along a continuum of undifferentiated pleomorphic sarcoma (UPS), myogenic UPS, and embryonal rhabdomyosarcoma (6, 7) . To develop a temporally-and spatially-restricted model of STS, we injected P7KP mice with 4-hydroxytamoxifen (4OHT) directly into the gastrocnemius muscle.
Remarkably, sarcomas developed at the 4OHT injection site with 100% penetrance with a median time that was approximately twice as fast as when the P7KP mice received systemic tamoxifen, which prompted us to test the hypothesis that more rapid sarcoma formation was caused by tissue injury related to 4OHT administration.
Although others have reported an association between injury and sarcoma development (8) (9) (10) (11) (12) (13) (14) , P7KP mice represent a unique model system to investigate the mechanism. P7KP mice are a mammalian system in which the timing of p53 loss and Kras activation is tightly controlled in a defined population of cells (muscle satellite cells). Our experiments demonstrate that the fate of Pax7+ cells harboring oncogenic mutations is altered in the setting of muscle injury in a process dependent on HGF/c-MET signaling. HGF/c-MET signaling plays an important role in regulating the proliferation of muscle progenitors following injury (15) , and we show that it is also required for rapid sarcoma formation in our model system. Therefore, we 4
propose that the activation state of the sarcoma cell of origin serves as a barrier to tumor formation. This tumor suppressor mechanism may explain why sarcomas are relatively rare.
MATERIALS AND METHODS

Mouse Experiments
Mice were maintained on a mixed 129 S4/SvJae and C57/Bl6 background. The
Pax7
CreER allele (B6;129-Pax7 tm2.1(cre/ERT2)Fan /J) has been described (16) . R26
LSL-YFP/YFP
(B6.129X1-Gt(ROSA)26Sor tm1(EYFP)Cos /J) reporter mice (17) were obtained from the Jackson
Laboratory. Kras LSL-G12D (18) and Trp53 mg/mL dissolved in PBS) and HGF (2 μg/mL dissolved in PBS) were delivered intramuscularly (IM) at a volume of 25 μL. 5'-Ethynyl-2'-Deoxyuridine (EdU), a thymidine analog that serves as a marker of cell proliferation, was dissolved in PBS at a concentration of 0.5 mg/mL and administered intraperitoneally at 10 μL per g of body weight. Tumor specimens were fixed in hematoxylin and eosin or with antibodies.
For HGF-mediated activation of satellite cells and assessment of P-MET expression in muscle, mice 2-4 months-of-age were treated with tamoxifen IP and corresponding IM injection (HGF to the tibialis anterior muscle or cardiotoxin to the gastrocnemius muscle, respectively). Mice treated with IM HGF were injected with IP EdU (10 μl 0.5 mg/mL per gram of body weight) for two subsequent days after IP tamoxifen/IM HGF. Three days after treatment, all mice were euthanized and the treated muscles were mounted on cork using Tragacanth (Sigma) and flash frozen for 30-45 seconds in 2-methylbutane (Sigma) cooled by liquid nitrogen. More specifically, in YFP/P-MET experiments, female Pax7
CreER/+ ; R26 YFP/YFP (P7Y) mice were given tamoxifen (Sigma) diluted to 20 mg/ml in corn oil, at 3 mg per 40 g body weight per intraperitoneal injection once a day consecutively for 5 days. Mice were anesthetized using 2,2,2-tribromoethanol (Sigma), which was dissolved in 2-methyl-2-butanol (Sigma). For quantification of P-MET/YFP double positive cells in injured and uninjured muscle, 25 μl of 40 μM cardiotoxin (Sigma) was injected with an insulin syringe into gastrocnemius muscles. 3 days later, mice were sacrificed and gastrocnemius muscles were harvested, fixed for 10 minutes in ice cold 4% paraformaldehyde (EMS) / 1x HALT phosphatase inhibitor (Thermo) / phosphate b in 20% sucrose / 1x HALT phosphatase inhibitor / PBS, then flash frozen as described above.
Immunohistochemistry and Immunofluorescence
All immunohistochemistry was performed using the Vectastain Elite ABC Kit (Mouse IgG) and 3,3'-Diaminobenzidine tetrahydrochloride (Sigma-Aldrich 
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Survival curves were compared with the log-rank test using GraphPad Prism software.
Statistical significance of values reported on bar graphs was deterimined using the Student's t test.
RESULTS
A temporally and spatially restricted model of STS
We previously developed a temporally and spatially-restricted mouse model of soft tissue sarcoma using intramuscular (IM) injection of an adenovirus expressing Cre recombinase (21) , which has been useful for surgical and radiation therapy experiments (22, 23) . However, adenovirus infects a heterogeneous population of cells. To generate a spatiallyrestricted tumor model where the cell of origin is better defined, we delivered 4OHT by IM injection into the gastrocnemius muscle of the left hindlimb of P7KP mice (6) to try to restrict genetic recombination and subsequent sarcoma formation to the site of injection. We treated 14 P7KP mice with an IM injection of 50 Pl of 10 mg/ml 4OHT dissolved in DMSO. As expected, all mice developed a tumor at the site of injection ( Figure 1A) . However, we were surprised to find the kinetics of tumor onset (median = 20 days, range 13-26 days) was faster than after IP tamoxifen (median 45 days, range 33-62 days) (6) (Figure 2A) . cardiotoxin-treated muscle, and no significant changes were seen in saline-treated muscle ( Figure 2C ).
Cardiotoxin-mediated injury also accelerates sarcoma formation in P7KP mice
The experiments described above indicate that IM injection of DMSO resulted in a tissue injury, leading to more rapid sarcoma formation. To further test this model, we next determined if IM injection of cardiotoxin could promote sarcoma formation in P7KP mice following systemic tamoxifen because muscle injury following administration of cardiotoxin has been extensively characterized ( Figure 2C ) (24). Eight P7KP mice were treated with IP tamoxifen and concurrent IM cardiotoxin ( Figure 3B ). Remarkably, all 8 mice developed palpable tumors at the cardiotoxin injection site with a median onset of 17 days (range 7-17 days). Thus, concurrent administration of systemic tamoxifen and injury with IM cardiotoxin in P7KP mice exerts temporospatial control over the formation of soft tissue sarcoma at the injury site.
We next studied the temporal relationship between tamoxifen-mediated recombination of p53 and Kras and cardiotoxin-mediated tissue injury. A time course experiment was performed whereby P7KP mice were injured with IM cardiotoxin at times before, after, and coincident with IP tamoxifen delivery ( Figure 3A,C) . When cardiotoxin-mediated injury was performed either just prior to recombination with tamoxifen (up to 3 days before) or at any timepoint thereafter (up to 21 days after), an injection site sarcoma formed within 20 days of cardiotoxin administration with nearly 100% penetrance (Figure 3B,D) . No sarcomas formed following treatment with cardiotoxin alone, as seen in other studies (14) . These results are consistent with a classic initiator/promoter model of sarcomagenesis whereby recombination with IP tamoxifen provides the initiating genetic insult, and injury serves as the promoter to drive sarcoma formation. The Hepatocyte Growth Factor/c-MET pathway promotes sarcoma formation in P7KP mice In the time course experiment, we were intrigued by the observation that recombined Pax7-expressing cells appeared to have reduced transformation potential until they were "activated" by cardiotoxin administration. Similar to recent experiments in squamous cell carcinoma (25) and intestinal cancer (26), we hypothesized that a key function of cardiotoxin might be to alter the activation state of Pax7-expressing satellite cells. We first assessed the number of proliferating satellite cells in P7KP mice following a single dose of systemic tamoxifen. For these experiments, P7KP mice (n=3 per group) were also treated with IM saline or hepatocyte growth factor (HGF), which has been shown to promote satellite cell proliferation both in vitro and in vivo (27, 28) . Of note, the IM injection volume to the tibialis anterior (TA) muscle for these experiments was reduced to 25 Pl in an effort to limit trauma related to the volume of injection (Supplementary Fig. 1A,B online) . The mice were given two consecutive daily doses of EdU and euthanized on day 3 after the IP tamoxifen and the IM HGF/saline injections. We collected the TA muscles and stained 10 Pm frozen sections for Pax7 and EdU ( Supplementary Fig. 2A,B online) . We counted 400 -600 satellite cells per mouse and determined the percentage that were EdU+ (Pax7, EdU double positive) as a measure of satellite cell activation. Interestingly, the vast majority of Pax7+ cells were not proliferating in mice treated with IM saline despite deletion of p53 and activation of Kras in Pax7-expressing cells throughout the animal (Figure 4A) . Administration of IM HGF caused a >3-fold increase in EdU uptake in satellite cells ( Figure 4A) . Moreover, evaluation of specimens by H&E staining revealed no significant inflammatory infiltrate ( Supplementary Fig. 2C online) . Thus, HGF promotes proliferation of recombined satellite cells without the histological hallmarks of tissue injury. Fig. 1C-E online) . All cardiotoxin-treated mice developed a sarcoma at the injection site with a median onset of 15 days, while only 3 of 12 saline-treated mice developed a sarcoma at the injection site ( Figure 4C ). In contrast, 11/13 mice treated with IM HGF developed a sarcoma at the injection site ( Figure 4C ). Of note, the sarcomas arising in HGF-treated mice occur with a median onset of 37 days, which is slower than sarcomas that arise following treatment with cardiotoxin ( Figure 4D) . Fig. 3 online) . This further proves that the c-MET pathway is required for sarcoma promotion in the context of injury in P7KP mice.
DISCUSSION
The P7KP mouse model of STS is a unique system to study the role of injury in tumorigenesis because it provides tight control of the timing of both genetic mutation (IP injection of tamoxifen) and injury (IM injection of cardiotoxin) prior to tumor formation. Other injury-mediated sarcoma model systems have been described, but they all lack the ability to control the timing of oncogenic mutations in a genetically engineered organism. Perhaps the most noteworthy model system was described by the laboratory of Dr. Bissell (8-10). They 
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in Pax7+ cells results in a significant decrease in the recruitment of proliferating satellite cells to the site of cardiotoxin injury (15) . In humans, the role of HGF/c-MET signaling is difficult to study in the context of acute injury because of the lack of available tissue samples. However, there was a small study of a group of human subjects that underwent a muscle biopsy of the quadriceps after completing a series of lengthening contractions (38) . A trend toward increased HGF protein expression in the muscle and blood following intense exercise was noted (38) . 
Our data also lend credence to patient reports of a localized injury causing their sarcoma (44) . In his landmark 1919 textbook "Neoplastic Diseases", James Ewing wrote that "sarcoma commonly develops after a single blow". When patients report a history of trauma prior to the development of sarcoma at the same location, such claims are difficult to substantiate in a rigorous manner and are frequently ignored by physicians. Here we report on the development of a temporally and spatially restricted mouse model of soft tissue sarcoma (STS) that allows for the precise timing of genetic mutations and tissue injury. Our data demonstrate that injury promotes sarcoma formation in a process dependent on HGF/c-MET signaling. Although "a single blow" is not likely to cause sarcoma, our results indicate that injury might promote sarcoma development by activating quiescent progenitor cells that have acquired oncogenic mutations. Hematoxylin and eosin stained slides show evidence of tissue injury in mice injected with DMSO or cardiotoxin (Scale bar = 150Pm). *** (p < 0.001). 
